Noroclav 250mg Tablets
Noroclav 250mg Tablets are for oral administration to dogs. Each Noroclav 250mg Tablet contains:
Amoxicillin as Amoxicillin Trihydrate 200mg
Clavulanic Acid as Potassium Clavulanate 50mg
Noroclav 250mg Tablets are indicated for treatment of the following infections caused by ?-lactamase producing strains of bacteria sensitive to amoxicillin in combination with clavulanic acid:
Skin infections (including superficial and deep pyodermas) caused by susceptible Staphylococci.
Urinary tract infections caused by susceptible Staphylococci or Escherichia coli.
Respiratory infections caused by susceptible Staphylococci.
Enteritis caused by susceptible Escherichia coli.
It is recommended to carry out suitable tests for sensitivity testing when initiating the treatment. The treatment should only proceed if sensitivity is proven to the combination.
Dosage & Administration
Administration: By the oral route. The tablets may be crushed and added to a little food.
Dosage Rate: 12.5mg combined actives/kg bodyweight twice daily. The recommended dose of 12.5mg per kg bodyweight is equivalent to one 250mg tablet per 20kg bodyweight.
Dosage frequency: The following tables are intended as a guide to dispensing Noroclav 250mg Tablets at the standard dose rate of 12.5mg/kg twice daily.
Contraindictions, Warnings etc
Do not use in rabbits, guinea pigs, hamsters or gerbils. Do not use in animals with known hypersensitivity to penicillin or other substances of the beta-lactam group.
Do not use in animals with serious dysfunction of the kidneys accompanied by anuria and oliguria.
Do not use where resistance to this combination is known to occur.
Hypersensitivity reactions unrelated to dose can occur with these agents.
Gastrointestinal symptoms (diarrhoea, vomiting) may occur after administration of the product.
Allergic reactions (e.g. skin reactions, anaphylaxia) may occasionally occur.
In case of occurrence of allergic reaction, the treatment should be withdrawn.
In animals with hepatic and renal failure, the dosing regime should be carefully evaluated.
Do not administer to horses and ruminating animals.
Studies in laboratory animals have not produced any evidence of teratogenic effects. Use only according to the benefit/risk assessment by the responsible veterinarian.
The potential for allergic cross-reactivity with other penicillins should be considered.
Penicillins may increase the effect of aminoglycosides.
Caution is advised in the use in small herbivores other than those reported in contradictions.
Chloramphenicol, macrolides, sulfonamides and tetracyclines may inhibit the antibacterial effect of penicillins because of the rapid onset of bacteriostatic action.
Do not store above 25°C; store in a dry place.
Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
Resistance to many antibiotics is caused by beta-lactamase enzymes which destroy the antibiotic before it can act on the bacteria themselves. The clavulanate in Noroclav Tablets counteracts this defence mechanism by inactivating the betalactamases, thus rendering the organisms sensitive to amoxicillin’s rapid bactericidal effect, at concentrations readily attainable in the body.
In vitro potentiated amoxicillin is active against a wide range of clinically important aerobic and anaerobic bacteria including:
Gram-positive: Staphylococci (including ?-lactamase producing strains); Clostridia; Streptococci
Gram-negative: Escherichia coli (including most ?-lactamase producing strains); Campylobacter spp; Pasteurellae; Proteus spp.